Normalizing Myocardial Carbohydrate Metabolism Reverses Energetic Impairment and Diastolic Dysfunction in a Rodent Model of Obesity

M. Dodd,D. Tyler,S. Neubauer,K. Clarke,J. Sourdon,A. Lewis
2014-11-25
Abstract:Background: The role of abnormal cardiac substrate metabolism in the development of obesity cardiomyopathy and the therapeutic potential of interventions targeting substrate metabolism are unknown. We hypothesised; (1) that obesity would impair both myocardial carbohydrate metabolism and energetics resulting in diastolic dysfunction and (2) that normalisation of carbohydrate metabolism would reverse these changes. Methods: Obese (n=36, 471±45g) and normal weight Long Evans rats (n=12, 383±34g) were diet standardized (67% carbohydrate, ≥5 days). We then performed in vivo hyperpolarized [1-13C] and [2-13C] magnetic resonance spectroscopy (MRS), echocardiography and perfused heart 31P MRS to evaluate myocardial metabolism, structure and function. Two obese groups were subsequently treated with either Liraglutide (a GLP-1 analogue, 0.2mg/kg twice daily, 7 days, n=12) or calorie restriction (70% usual intake, 28 days, n=12) and then restudied. Results: Obesity caused left ventricular (LV) hypertrophy (2.1 vs 1.8mm, P Conclusions: Treatment with either Liraglutide (weight-neutral) or calorie restriction normalized myocardial carbohydrate metabolism, energetics and diastolic function. These findings suggest a key role for myocardial metabolism in the development of obesity cardiomyopathy and identify PDH as a potential clinical therapeutic target.
Medicine
What problem does this paper attempt to address?